About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
- 2014 Rate Card & Production Specs
- 2013 Rate Card & Production Specs
- Advertising Due Dates
- BPA Statement
Statement of Purpose
Guidelines for Authors
Erythropoietic Therapy: Dosing Patterns and Calculated Cost Assessment for Pre-dialysis Chronic Kidney Disease Patients In a Managed Care Setting
In a comparison of two erythropoiesis-stimulating agents, drug costs were found to be lower for epoetin alfa than for darbepoetin alfa.
John J. Barron, PharmD, W. Daniel Grochulski, PhD, Samir H. Mody, PharmD, MBA, Brahim K. Bookhart, MBA, MPH, and R. Scott McKenzie, MD
Analysis and Opinion
Although far from perfect, the FDA Amendments Act gives the FDA more funds and authority, for example, in overseeing drug distribution and in forcing manufacturers to provide drug guides and to perform post-approval safety trials.
There won’t be any juicy industry gossip or corporate intrigue, but Johnson & Johnson and GlaxoSmithKline hope that their new blogs will at least set the record straight about their companies and products.
Topics include galiximab, bendamustine, and rituximab for hematological malignancies; pazopanib for renal cell cancer; trastuzumab and lapatinib for breast cancer; sorafenib/temozomide for melanoma; and IRX-2 for head and neck cancer
Marvin M. Goldenberg, PhD, RPh, MS
Presentations cover advances in therapies for breast, prostate, and renal cancers and melanoma; adalimumab for patients with Crohn’s disease and fistula; and infliximab for the treatment of ulcerative colitis and colectomy.
Notice how we haven’t aged a bit in five years!
David Nash, MD, MBA, explains how a new initiative encourages the participation of previously underrepresented groups in clinical trials, including the elderly, minorities, and rural residents.
David B. Nash, MD, MBA
Stephen Barlas discusses the Community Pharmacy Fairness Act, which might help independent pharmacies in their struggle to compete for customers being forced to use mail-order programs.
In Part 1 of a two-part series, Matthew Grissinger, RPh, FASCP, describes the factors that often contribute to the problem of unsafe patient-controlled analgesia.
Matthew Grissinger, RPh, FASCP
From Abilify to Trasylol, P&T presents the latest information on FDA approvals, new indications, and industry updates.
The authors review selegiline orally disintegrating tablets (Zelapar) for Parkinson’s disease.
Marilena S. Antonopoulos, PharmD, and Kristine S. Kim, PharmD